Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes

Joseph W. Polli*, Joan E. Humphreys, Kelly A. Harmon, Lindsey O. Webster, Mindy J. Reese and Christopher C. MacLauchlin

GlaxoSmithKline Inc, Research Triangle Park, NC, USA

Abstract

Type 2 diabetes mellitus is a chronic disease characterized by progressive deterioration of glycemic control and an increased risk of associated complications. Remogliflozin etabonate is the ester prodrug of remogliflozin, a selective sodium-dependent glucose transporter-2 inhibitor that was under development to treat type 2 diabetes. This work investigated the in vitro inhibition of efflux and uptake transporters and cytochrome P450 enzymes by remogliflozin etabonate, remogliflozin and a number of other metabolites. As well, the ability of remogliflozin to induce cytochrome P450 enzymes in human hepatocytes was examined. Remogliflozin etabonate, remogliflozin and GSK279782 (an active pharmacological metabolite of remogliflozin) were inhibitors of organic anion transporting polypeptide-1B1 with IC₅₀ values of 5.3, 25 and 14 µM, respectively. Remogliflozin etabonate and remogliflozin were inhibitors of organic cation transporter-1 with IC₅₀ values of 43 and 39 µM, respectively. In contrast, remogliflozin etabonate, remogliflozin, GSK279782, and GSK333081 (a metabolite of remogliflozin) were not inhibitors of P-glycoprotein, a number of other renal transporters, or cytochrome P450 enzymes. Further, three circulating glucuronide metabolites found in human plasma were not inhibitors of cytochrome P450 enzymes or organic anion transporters. Remogliflozin etabonate, but not remogliflozin or GSK279782, activated the pregnane X Receptor in vitro. Further studies demonstrated that remogliflozin (up to 100 µM) did not induce cytochrome P450 3A4 or 1A1 mRNA in human hepatocytes; however a small increase was noted for CYP2B6 mRNA. Combined with pharmacokinetic data from healthy volunteers and diabetic subjects, these in vitro investigations provide a low drug interaction potential for remogliflozin etabonate, remogliflozin and the associated metabolites to be perpetrators of clinical drug interactions. This information has been used to guide the design of clinical studies with remogliflozin etabonate when given with other co-medications.

Keywords: Diabetes, SGLT2 inhibitors; Transporters; Drug integrations; Cytochrome P450 enzymes

Abbreviations: Pgp: P-glycoprotein; MDCK: Madin Darby Canine Kidney cells; IC50: Concentration required for 50% Inhibition; SGLT2: Sodium-Dependent Glucose Co-transporter-2; UKPDS: United Kingdom Prospective Diabetes Study; ABC: ATP Binding Cassette Family; SLC: Solute Carrier Family; PXR: Pregnane X Receptor

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by progressive deterioration of glycemic control and an increased risk of associated complications. Evidence from clinical trials suggests that improving glycemic control can substantially reduce the long-term microvascular and macrovascular complications of diabetes [1-3]. Current guidelines recommend that T2DM patients should be initially managed with diet and exercise followed by pharmacological treatment, which typically involves patients taking multiple medications [4,5]. Sodium–dependent glucose co-transporter (SGLT) inhibitors are an exciting new class of anti-diabetic agents [6-9]. These drugs act by competitively inhibiting the SGLT proteins, thus blocking intestinal and renal absorption of glucose. Inhibition of SGLTs has been shown to translate to a reduction in plasma glucose concentrations with a low incidence of hypoglycemia [9].

Within the SGLT family of transporters, the SGLT1 and SGLT2 proteins have been active drug targets for over a decade. SGLT1 is a high-affinity, low-capacity glucose/galactose co-transporter primarily expressed in the intestine, which is also expressed at lower levels in the kidney [10,11]. In contrast, SGLT2 is a low-affinity, high-capacity glucose transporter that is specifically expressed in the renal proximal tubule at high levels. Of the approximately 180 g of plasma glucose filtered and reabsorbed by the kidney each day, the vast majority (80 to 90%) of the glucose uptake activity is associated with SGLT2, with SGLT1 having a more modest (10-20%) contribution [9]. Therefore, selective inhibition of SGLT2 has become an attractive drug target [10,12,13]. Indeed, it has been clearly demonstrated in numerous clinical studies that pharmacological inhibition of SGLT2 results in glucosuria, which leads to reductions in post-prandial and fasting plasma glucose concentrations [8,13].

Remogliflozin etabonate (GSK189075; KGT-1681) is the prodrug of remogliflozin (GSK189074; KGT-1650), the active entity that inhibits SGLT2 [14,15]. Remogliflozin is a potent and selective SGLT2 inhibitor with an in vitro IC₅₀ value of 12.4 nM [15]. Oral administration of remogliflozin etabonate reduced postprandial glucose excursions without inducing hypoglycemia, improved plasma glucose concentrations in subjects with diabetes, and reduced glycosylated hemoglobin (HbA1c) levels [14]. The objective of this work was to investigate the in vitro
inhibition of efflux/uptake transporters and cytochrome P450 (CYP) enzymes, and the potential impact of remogliflozin etabonate, remogliflozin and metabolites to cause drug interactions. From these in vitro and in vivo investigations, a mechanistic basis for elucidating potential clinical drug interactions has been developed to guide the design of future clinical studies with remogliflozin etabonate.

Materials and Methods

Materials

GlaxoSmithKline Chemical Development supplied [3H]-remogliflozin etabonate (55-57 mCi/mmol), remogliflozin etabonate, remogliflozin, GSK279782 (active metabolite), GSK333081 (metabolite), GSK1997711 (glucuronide metabolite), GSK1997714 (glucuronide metabolite), GSK355993 (glucuronide metabolite) and GFI120918 (Elacridar). [3H]-digoxin (5 Ci/mmol), [3H]-estradiol 17β-D-glucuronide (45.0 Ci/mmol), [14C]-p-Aminophippuric acid (53 Ci/mmol), [3H]-prostaglandin F2a (155 Ci/mmol), [3H]-estrone sulfate (57 Ci/mmol), and [3H]-histamine (18 Ci/mmol) were supplied by Perkin Elmer Life Sciences (Boston, MA). [3H]-Tetraethylammonium (55 mCi/mmol) was purchased from American Radiolabeled Chemicals (St. Louis, MO) and [3C]-uric acid (52 mCi/mmol) was purchased from Moravek Biochemicals (Brea, CA). Ethoxyresorufin (ER) was purchased from Biomol (Plymouth Meeting, PA) and 7-benzyloxyquinoline (7BQ) was purchased from BD Biosciences (Hemshaw, MA). Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO). Transwells (12-well, 11-mm diameter, 0.4 µm pores) were purchased from Corning Costar (Cambridge, MA).

Pgp inhibition assays

Cell culture and transport inhibition studies were completed as described [16] using the MDCK-MDR1 cell line. Remogliflozin etabonate, remogliflozin, and selected metabolites were tested in triplicate at a minimum of six concentrations spanning 0.1 to 100 µM for Pgp inhibition. Inhibition studies were conducted for 90 min using [3H]-digoxin (27 nM) as the probe substrate. [3H]-Digoxin was quantified by liquid scintillation counting (LSC) by using a 2900TR radioactivity quantified by LSC.

OAT, OCT, and URAT inhibition assays

For OAT and OCT inhibition assays, transporter expressing 24-well tissue culture plates individually expressing either OAT1, OAT2, OAT3, OAT4, OCT1, OCT2, OCT2-A, or OCT3; the parental S2 cell line is derived from the S2 portion of the renal proximal tubules and carries a temperature-sensitive simian virus 40 large T-antigen gene [18]. For URAT inhibition assays, transporter expressing HEK-293 cells were seeded in 24-well Biocoat plates (Becton Dickinson, Franklin Lakes, NJ) at a cell density of 105 cells/well. Transporter expressing cells were cultured for 2 days at 33°C (S2 cells) or 37°C (HEK293 cells) as described [18]. Remogliflozin etabonate, remogliflozin, metabolites and positive control inhibitors (probenecid, quinidine and benzbromarone for OATs, OCTs, and URAT1, respectively) were dissolved in DMSO and then diluted to a final concentration of 30 μM into uptake medium (DPBS pH 7.5 for S2 cells or Hank’s balanced salt solution (HBSS) pH 7.4 containing no Cl− for HEK293 cells) containing the radiolabeled substrates. Monolayers were incubated for 2 min (OAT1, OAT3 and OAT4), 0.5 min (OAT2), 15 min (OCT1), 5 min (OCT2 and OCT2-A), 1 min (OCT3) or 5 min (URAT1). After incubation, the solution was removed and uptake stopped by adding ice-cold DPBS (or HBSS). Cells were lysed with 0.1 M sodium hydroxide, lystate collected and radioactivity determined by LSC. Protein concentrations of cellular lysates were determined using a BCA Protein Assay Reagent (Pierce, Rockford, IL) as described by the manufacturer.

Cyp inhibition assays

The inhibition of CYP enzymes (CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) by remogliflozin and GSK279782 was assessed in human liver microsomes (pool of 16 individuals; XenoTech LLC, Lenexa, Kansas) using LC/MS based methods as described [19,20], while the metabolites (GSK333081, GSK1997711, GSK1997714, GSK355993) were assessed in recombinant (CYP 1A2, 2C9, 2C19, 2D6 and 3A4) enzymes (bacteria, 10 mg/mL; XenoTech LLC) using fluorescence based methods as described below.

Human liver microsomes: The ability of remogliflozin or GSK279782 to inhibit CYP enzymes in a direct and metabolism-dependent manner was investigated with a pool of human liver microsomes [19,20]. Duplicate incubations (250µL) were conducted at 37°C containing potassium phosphate buffer (50 mM, pH 7.4), an NADPH-generating system (1.7 mg NADP+, 7.8 mg glucose-6-phosphate, and 6 units of glucose-6-phosphate dehydrogenase per mL), human liver microsomes (0.1 mg/mL), inhibitor (or solvent) and probe substrate at approximately the Km. The probe substrates were: CYP 1A1 - phenacetin; 2A6 - coumarin; 2B6 - bupropion; 2C8 - rosiglitazone; 2C9 - diclofenac; 2C19 - mefenpyr; 2D6 - buforal; 3A4 - atorvastatin, midazolam, and nifedipine. Reactions were initiated by addition of the NADPH regenerating system after pre-warming at 37°C for 5 minutes to assess direct inhibition. To examine metabolism-dependent inhibition, remogliflozin, GSK279782, or positive control were preincubated at 37 °C with human liver microsomes and an NADPH-generating system for 20 minutes. After the preincubation period, the probe substrate was added, and the incubation continued for 5 or 10 min. Known direct and metabolism-dependent inhibitors were included as positive controls [19]. Reactions were terminated by the addition of 250 µL acetonitrile, centrifuged to remove protein,
spiked with an internal standard and analyzed by LC-MS/MS on a Sciex API3000 or equivalent using a validated method for the detection of probe substrate metabolites. Analyte/internal standard peak area ratios and the metabolite concentrations were determined by interpolation from the appropriate standard curve. Rates of metabolite production at each concentration of remogliflozin, GSK279782, or positive control inhibitor, were expressed as a percentage of the mean uninhibited control rate for each assay.

Recombinant: Duplicate (250µL) incubations were conducted at 37°C containing potassium phosphate buffer (50 mM, pH 7.4), an NADPH-generating system (1.7 mg NADP+), 7.8 mg glucose-6-phosphate, and 6 units of glucose-6-phosphate dehydrogenase per mL), recombiant enzyme (0.1 mg/mL), inhibitor (or solvent) and probe substrate at approximately the Km. The probe substrates were: CYP 1A2 ethoxyresorufin; 2C9 – 7-methoxy-4-trifluoromethylocoumarin-3-acetic acid; 2C19 – 3-butyryl-7-methoxy coumarin; 2D6 – 4-methy lamino methyl-7-methoxy coumarin; 3A4 – diethoxy fluorescein and 7-benzoxoxyquinoline

Reactions were initiated by addition of the NADPH regenerating system after pre-warming at 37°C for 10 minutes. GSK1997711, GSK1997714 or GSK355993 were tested at final concentrations of up to 300 µM and GSK333081 up to 100 µM. Incubations with miconazole were used to confirm an appropriate inhibition response. The probe substrates (the exception of ER and 7BQ) were designed based on reported CYP structure activity relationships and synthesized in-house at GlaxoSmithKline [International Patent Application WO 00/22159, 2000; WO 02/12542, 2002; WO 99/58710, 1999; WO 01/44495, 2001]. The incubation plate was analyzed using a fluorescence plate reader with the excitation and emission wavelengths optimized for each of the metabolites derived from the probe substrate. SoftMax Pro (v3.1.2, Molecular Devices, Sunnyvale CA) calculated the change of fluorescence intensity over 10 scan cycles and expressed the results as the rate (slope). The percentage of remaining enzyme activity was determined using Excel (v. 2002 SP3); the rate of the vehicle control (solvent only) was set at 100%. Rates of metabolite production at each concentration of inhibitor were expressed as a percentage of the mean uninhibited control rate for each assay.

PXR activation assay

Cell culture and pregnane X receptor (PXR) activation studies were completed as described [21]. HuH7 cells were seeded onto 96 well microtitre plates at a seeding density of 180,000 cells/mL (each well received 18,000 cells) and plates incubated overnight at 37°C. The next day, cells were transfected with a human PXR/SPAP reporter gene and incubation with test article, the wells were assayed for SPAP and run at 10^3 gene and protein concentrations covering 0.01 to 10^3 µg/mL. Duplicate (250µL) incubations were conducted at 37°C containing potassium phosphate buffer (50 mM, pH 7.4), an NADPH-generating system (1.7 mg NADP+), 7.8 mg glucose-6-phosphate, and 6 units of glucose-6-phosphate dehydrogenase per mL), recombiant enzyme (0.1 mg/mL), inhibitor (or solvent) and probe substrate at approximately the Km. The probe substrates were: CYP 1A2 ethoxyresorufin; 2C9 – 7-methoxy-4-trifluoromethylocoumarin-3-acetic acid; 2C19 – 3-butyryl-7-methoxy coumarin; 2D6 – 4-methy lamino methyl-7-methoxy coumarin; 3A4 – diethoxy fluorescein and 7-benzoxoxyquinoline

Reactions were initiated by addition of the NADPH regenerating system after pre-warming at 37°C for 10 minutes. GSK1997711, GSK1997714 or GSK355993 were tested at final concentrations of up to 300 µM and GSK333081 up to 100 µM. Incubations with miconazole were used to confirm an appropriate inhibition response. The probe substrates (the exception of ER and 7BQ) were designed based on reported CYP structure activity relationships and synthesized in-house at GlaxoSmithKline [International Patent Application WO 00/22159, 2000; WO 02/12542, 2002; WO 99/58710, 1999; WO 01/44495, 2001]. The incubation plate was analyzed using a fluorescence plate reader with the excitation and emission wavelengths optimized for each of the metabolites derived from the probe substrate. SoftMax Pro (v3.1.2, Molecular Devices, Sunnyvale CA) calculated the change of fluorescence intensity over 10 scan cycles and expressed the results as the rate (slope). The percentage of remaining enzyme activity was determined using Excel (v. 2002 SP3); the rate of the vehicle control (solvent only) was set at 100%. Rates of metabolite production at each concentration of inhibitor were expressed as a percentage of the mean uninhibited control rate for each assay.

Induction of CYP mrna in human hepatocytes

Primary human hepatocytes were obtained commercially plated in a sandwich configuration on a collagen substratum with Matrigel overlay (Invitrogen, Carlsbad, CA). Hepatocytes were treated with remogliflozin, positive control inducers or 0.1% DMSO dissolved in Modified Chee’s Medium (MCM) for 48 hours. After the treatment period, cells were harvested with 1:1 mixture of RLT (Qiagen, Valencia, CA) and TRIZOL (1:1) (Invitrogen, Carlsbad, CA) and stored at -80°C until analysis. Total RNA was extracted from hepatocytes by column extraction using a Qiagen RNeasy® 96 RNA extraction kit (Qiagen, Valencia, CA). Following extraction, samples were DNase treated and quantified using a Ribogreen® RNA quantitation kit ( Molecular Probes, Eugene, OR), and cDNA was synthesized using Superscript II® RNase H- reverse transcriptase (Invitrogen, Carlsbad, CA). The resultant cDNA template was used to quantify the number of copies of mRNA for selected CYP genes using an ABI 7900 Sequence Detection System (Applied Biosystems Inc., Foster City, CA). Serially diluted human genomic DNA was used as a standard for determining the relative copy number of each CYP gene. The resulting copy numbers were normalized to the total RNA concentration, and the fold change of treated samples compared to vehicle treated samples was calculated. Sequences of primers and probes used in TaqMan assay were:

| Gene  | Forward Primer | Probe | Reverse Primer |
|-------|----------------|-------|----------------|
| CYP1A2 | AGGCACCGCCGCT-GTGA | CATGCCAGCC-GGCGGTGC | GGTT-GCTCTTCCAT-GATGAGAA |
| CYP2B6 | TCCCGCGCTCTC-TAGACAAAT | CTCTGACTCCCT-GCAACTCTT | CTGGCTTGAGCC-GTCTCTCA |
| CYP3A4 | TCTCGGTGTTCCTCAG- GCCACAGA | CGTGTC-GACCTTCCACT-GAACC |
| GADPH | CAAGGCATTCATC-GACAATTTTG | ACCAGCATCAC-GGCCATCGTGGCA | GGGCCATCAC-GGACATCTTGC |

Whole-body autoradiography

All dosing procedures were done according to the approved Institutional Animal Care and Use Committee protocols. The tissue distribution of radioactive drug-related material in the male Lister-Hooded rats (Charles River Laboratories, UK) following a single oral dose of 25 mg/kg [14C]-remogliflozin etabonate (formulated in 0.1% (w/v) 400 cps methylcellulose containing 0.1% (v/v) Tween 80) was investigated using whole-body autoradiography at 0.25, 1, 4, 24 hours, 3 days and 28 days hours after dose administration (n=1 animal per time point). Tissue processing and image analysis were completed as described [22-24]. Sections were imaged using [14C]-sensitive Fuji imaging plates (BAS-MS, Raytek Scientific Ltd, Sheffield, UK) and the plate scanned (FUJI FLA-5000 radioluminography system, Raytek Scientific Ltd, Sheffield, UK). The resulting images were read and stored using FUJI FLA-3000 Image Reader software version 2.0 from the Applied Biosystems Inc., Foster City, CA. The remaining images were imaged and stored using Seescan Densitometry image analysis software (version 1.3 (build 136); Lablogic PLC, Sheffield, UK).

Calculations

For transporter and CYP inhibition studies, the IC50 values (the concentration of inhibitor required for 50% inhibition of the monolayer transport, cellular uptake or metabolite production rates) were calculated with GraFit (version 5.06, Erithacus Software Limited, London, UK) using:
Background metabolism of remogliflozin etabonate

The metabolism of remogliflozin etabonate has been extensively characterized (Figure 1) [25]. This work focused on the potential perpetrator drug interactions that remogliflozin etabonate and its metabolites could have on other therapeutic agents. The rationale for testing of remogliflozin etabonate, remogliflozin and its metabolites in these assays is as follows. Remogliflozin etabonate is a prodrug that is rapidly metabolized by cellular esterases to remogliflozin, the active SGLT2 inhibitor. Remogliflozin undergoes further metabolism by CYP enzymes directly yielding GSK279782 and GSK333081, and non-CYP mediated pathways such as glucosidases and UDP-glucuronosyltransferases ultimately yielding glucuronide metabolites. Remogliflozin and GSK279782 are both potent SGLT2 inhibitors (in vitro Ki values ~ 12 nM) [15] and account for the majority of the pharmacological activity in vivo [26]. Of the four non-glucuronide analytes, remogliflozin is the major circulating metabolite, with GSK279782 being 16-22% of remogliflozin exposure. In contrast, GSK333081 has an in vitro Ki of ~30 nM and exposures of ~6% of remogliflozin; thus, it is not expected that GSK333081 contributes significantly to the in vivo pharmacological activity in humans. Remogliflozin etabonate does not have pharmacological activity and is <2% of the remogliflozin exposure [15]. The final end products of remogliflozin metabolism are three inactive glucuronide conjugates (GSK1997711, GSK1997714, GSK355993), which are eliminated almost exclusively in the urine [25]. GSK1997711 is the largest circulating metabolite, representing 48% of the dose.

ATP-Binding Cassette (ABC) and Solute Carrier (SLC) transport inhibition assays

The inhibition of Pgp (concentration range 0.1 to 100 µM) by remogliflozin etabonate, remogliflozin, GSK279782, and GSK333081
The radiolabeled substrate in the absence or presence of 30 µM of GSK333081 and GSK333081 on a panel of human renal transporters was investigated in S2 cells stably expressing organic anion etabonate, remogliflozin, and GSK279782 (Table 1).

### Table 1: Inhibition of Human ABC and SLC Transporters by Remogliflozin etabonate, Remogliflozin and Metabolites.

| Transporter | IC₅₀ (µM) | Transporter | IC₅₀ (µM) | Probe Substrate |
|-------------|----------|-------------|----------|----------------|
| Pgp         | >100     | Remogliflozin | >100 | GS10279782 | GSK333081 |
| OATP1B1     | 5.3 (1.1) a | Remogliflozin | 25 (2.3) | NT | [14C]-digoxin |
| OCT1        | 43.4 (3.7) | Remogliflozin | 38.6 (1.6) | ≤100 | [3H]-digoxin |
| OCT3        | >100     | Remogliflozin | >100 | >100 | >100 |

*Data are the mean (± standard deviation) from triplicate wells. NT: Not Tested

was assessed by determining the B→A transport of [3H]-digoxin across MDCKII-MDR1 monolayers. Neither remogliflozin etabonate, remogliflozin, nor the metabolites were inhibitors of Pgp (IC₅₀ values >100 µM; Table 1). In contrast, remogliflozin etabonate, remogliflozin, and GSK279782 inhibited the OATP1B1-mediated uptake of [3H]-estradiol 17β-D-glucuronide ([H]-EG) in the CHO-OATP1B1 cell line. The IC₅₀ values were 5.3, 25, and 14 µM respectively for remogliflozin etabonate, remogliflozin, and GSK279782 (Table 1).

The inhibitory effect of remogliflozin etabonate, remogliflozin, GSK279782 and GSK333081 on a panel of human renal transporters was investigated in S2 cells stably expressing organic anion transporter 1 (OAT1), OCT1, and OCT2, or OAT4, the organic cation transporter 1 (OCT1), OCT2 (isoform a), OCT2-A (isoform b) or OCT3, and HEK293 cells expressing urate transporter 1 (URAT1). For each transporter, transfected cells were initially incubated with the radiolabeled substrate in the absence or presence of 30 µM of remogliflozin etabonate, remogliflozin, GSK279782 or GSK333081 (Table 2). Of the nine transporters tested, only OCT1 and OCT3 showed >20% inhibition by remogliflozin etabonate, remogliflozin, or the metabolites. Due to this notable inhibition, a follow up study was completed to determine IC₅₀ values against OCT1 and OCT3. Remogliflozin etabonate and remogliflozin inhibited OCT1 with IC₅₀ values of 43 and 39 µM, respectively, while GSK29782 and GSK333081 had IC₅₀ values >100 µM (Table 1). All four compounds had IC₅₀ values >100 µM for OCT3, demonstrating weak inhibition of this transporter. Finally, the three circulating glucuronide metabolites GSK1997711, GSK1997714 and GSK355993 were tested as OCT1, 3 and 4 inhibitors (0.1 to 300 µM) as they are eliminated in the urine [25]. None of these compounds inhibited the OCT transporters (data not shown).

### CYP inhibition assays

The inhibition of CYP enzymes by remogliflozin and GSK279782 was assessed using an LC/MS based methods (CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) while the metabolites (GSK333081, GSK29782, and GSK333081) were tested as OAT1, 3 and 4 inhibitors.
GSK1997711, GSK1997714, and GSK355993) were assessed using fluorescence based methods (CYP 1A2, 2C9, 2C19, 2D6 and 3A4). Remogliflozin etabonate was not tested due to its instability in the cell culture conditions. After incubation for 48 hours with remogliflozin (1, 10 or 100 µM), there was no notable induction (<20% of prototypical inducer) of CYP1A2 or CYP2B6 (Table 4). As well, remogliflozin and GSK279782 were not metabolism dependent inhibitors (data not shown).

### CYP induction assays

The CYP induction potential of remogliflozin etabonate, remogliflozin and GSK279782 were assessed using a pregnane X receptor (PXR) assay and the potential of remogliflozin to induce CYP mRNA was assessed using human hepatocytes. Remogliflozin etabonate (0.01 to 10 µM) activated PXR in vitro to 71% compared to the maximum of the positive control (10 µM rifampicin). In contrast, remogliflozin and GSK279782 (0.01 to 10 µM) did not activate PXR (< 15% of control). Because of the activation seen by the prodrug remogliflozin etabonate, remogliflozin was investigated for its ability to induce CYP mRNA in human hepatocytes; remogliflozin etabonate was not tested due to its instability in the cell culture conditions. After incubation for 48 hours with remogliflozin (1, 10 or 100 µM), there was no notable induction (<20% of prototypical inducer) of CYP1A2 or 3A4 mRNA (Table 4). There was a small increase in CYP3A4 mRNA in one of three human hepatocyte preparations as reflected in the 5-fold change and associated large standard deviation. However, the mean 5-fold change was well below the 50-fold induction observed with 50 µM rifampicin, a prototypical CYP3A4 inducer. However, at 100 µM, remogliflozin did show a small induction of CYP2B6 mRNA (~26% of the response seen with phenobarbital (200 µM), a prototypical inducer of the CYP2B6 gene).

**Whole-body autoradiography in rats**

The tissue distribution of [14C]-remogliflozin etabonate was determined in six male rats by using whole-body autoradiography at 0.25, 1, 4, 24 hours, and 28 days after oral administration (n = 1 animal per time point). The absorption of radioactivity following a single oral dose of 25 mg/kg [14C]-remogliflozin etabonate yielded widely distributed radioactivity into tissues with the exception of brain and was cleared from most tissues by 24 hours post dose, mainly by biliary and renal elimination (Figure 2 and Table 5). Tissues with the highest radioactivity included the liver, kidney, and hardier gland. Only low levels of radioactivity were detected in the central nervous system (CNS) at any time (brain-to-plasma ratios <0.15).

**Discussion**

SGLT2 inhibitors are a new class of potential anti-diabetic drugs [6,8,12]. A number of small molecule SGLT2 inhibitors are/have been under clinical development, including the first orally absorbable SGLT inhibitor T-1095 [26], sergliflozin etabonate (GW868682) [27,28], remogliflozin etabonate (GSK189075) [14], and dapagliflozin (BMS-512148) [29,30]. Remogliflozin etabonate is a novel member of the beta-D-glucopyranoside class of SGLT2 inhibitors with in vitro Ki values near 12 nM [15]. In addition, as large (molecular weight range 408 to 523) and lipophilic (clogP range = 1.7 to 2.7) molecules, remogliflozin etabonate, remogliflozin and GSK278782 are typical of drugs that interact with ABC efflux and SLC transporters [31]. It was therefore of interest to investigate the interaction of remogliflozin etabonate and its metabolites with drug transporters to assess the potential for drug interactions.

Remogliflozin etabonate, remogliflozin and GSK279782 were inhibitors of OCT1B1 (IC50 values of 5.3, 25 and 14 µM, respectively), and remogliflozin etabonate and remogliflozin were inhibitors of OCT1 (IC50 values of 43 and 39 µM, respectively). In contrast, GSK333081 was not an inhibitor of OATP or OCT1. Further, remogliflozin etabonate, remogliflozin, GSK279782 and GSK333081 were not inhibitors of Pgp, OCT2, OCT2A, OCT3, OAT1, OAT2, OCT4 or URAT1. These IC50 values for OATP1B1 and OCT1 inhibition are much higher than the range of peak plasma concentrations following a 100 mg BID dose [14] (remogliflozin etabonate = 0.03 µM or 14.7 mg/mL; remogliflozin = 0.95 µM or 427 mg/mL; GSK279782 = 0.13 µM or 54.8 mg/mL) suggesting little potential for transporter-mediated drug interactions, even when taking into consideration the potential 3- to 12-fold higher absorption of the ligand in the small intestine.

**Table 4:** Induction of Cytochrome P450 mRNA by Remogliflozin in Human Hepatocytes.

| Treatment | Mean mRNA Expression (Mean ratio of treated over control *) | Tissue-to-Blood Ratio |
|-----------|-------------------------------------------------------------|----------------------|
| 1 µM Remogliflozin | CYP1A2: 1.1 ± 0.16; CYP2B6: 1.0 ± 0.057; CYP3A4: 0.84 ± 0.19 | Blood: 2.92, 3.56, 1.02, 0.15, 1.00, 1.00, 1.00 |
| 10 µM Remogliflozin | CYP1A2: 1.7 ± 1.4; CYP2B6: 1.4 ± 0.18; CYP3A4: 1.7 ± 0.26 | Brain: 0.24, 0.53, 1.24, 0.31, 0.43, 1.05, 1.21, 2.10 |
| 100 µM Remogliflozin | CYP1A2: 1.6 ± 0.38; CYP2B6: 2.2 ± 0.72; CYP3A4: 5.0 ± 2.4 | Kidney: 11.0, 14.1, 3.96, 0.41, 3.75, 3.97, 3.87, 2.79 |
| Prototypical Inducer | CYP1A2: 110 ± 83; CYP2B6: 6.6 ± 1.2 (PB); CYP3A4: 14 µM (Rif) | Liver: 32.8, 16.3, 9.06, 1.72, 11.2, 4.57, 8.87, 11.7 |
| | | Muscle: 0.75, 1.65, 0.47 | 0.26, 0.46, 0.46, 0.46 |

*Controls are defined as 0.1% (v/v) DMSO; Values are expressed as a mean ± standard deviation of 3 human hepatocyte preparations. The criterion for notable induction is a response by the test compound that is greater than 20% of the response seen by the prototypical inducer

**Table 5:** Tissue Concentrations and Tissue-to-Blood Ratios of Radioactivity in Male Rats After a Single Oral Administration of 25 mg/kg [14C]-Remogliflozin etabonate.

| Tissue | Concentration (µg equivalents/g tissue) | Tissue-to-Blood Ratio |
|--------|----------------------------------------|----------------------|
| Blood | 3.56 ± 1.02, 0.15 | 1.00, 1.00, 1.00 |
| Brain | 0.53 ± 0.14 | 0.08, 0.15, 0.14 |
| Hardier Gland | 1.24 ± 0.31 | 0.43, 1.05, 1.21, 2.10 |
| Heart | 2.58 ± 0.07 | 0.90, 0.76, 0.70, 0.64 |
| Kidney | 14.1 ± 3.96 | 3.75, 3.97, 3.87, 2.79 |
| Liver | 16.3 ± 9.06 | 11.2, 4.57, 8.87, 11.7 |
| Muscle | 0.47 | 0.26, 0.46, 0.46, 0.46 |

*Abbreviations: BLQ: Below Limit of Quantification; NC = Not Calculated

**Figure 2:** Whole-body autoradiogram of a male rat 4 hours after a single oral administration of [14C]-Remogliflozin etabonate at a dose of 10 mg/kg in 0.5% (v/v) aqueous hydroxypropyl methyl cellulose containing 0.1% (v/v) Tween 80. Tissue processing and image analysis were completed as described in Material and Methods. Digital images were obtained by phosphorimaging. Abbreviations: bf: brown fat; ed: epdidymis; Hd: hardier gland; nm: nasal mu-
cosa; pg: preputial gland; pr: prostate; sg: salivary gland; skn: non-pigmented skin; skp: pigmented skin; sv: seminal vesicles; ts: testis.

**Citation:** Polli JW, Humphreys JE, Harmon KA, Webster LO, Reese MJ, et al. (2012) Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes. J Diabetes Metab 3:200. doi:10.4172/2155-6156.1000200
total drug and metabolite burden in tissues such as the kidney and liver as observed in the whole-body autoradiography study (Figure 2 and Table 1).

Remogliflozin etabonate, remogliflozin and its metabolites were also tested for in vitro inhibition or induction interaction with CYP enzymes. Remogliflozin and GSK279782 were not direct or mechanism-based inhibitors of eight CYP enzymes (Table 3). Further, GSK333081 and the three circulating glucuronide metabolites were also not direct inhibitors of CYP enzymes. Remogliflozin etabonate, but not remogliflozin or GSK279782, activated PXR in vitro with some potency (71% of the prototypical inducer response when tested up to 10 clinical Cmax for remogliflozin M). This observation was followed up with a human hepatocyte study using remogliflozin as the etabonate prodrug was not stable in the cell culture conditions. Remogliflozin (up to 100 μM) did not induce CYP3A4 or 1A1 mRNA in human hepatocytes. However a small increase was noted for CYP2B6 mRNA. This response was only 26% of the prototypical inducer phenobarbital and was observed only at the high dose tested (100 μM), which is 100-times higher than the observed clinical Cmax for remogliflozin following 100 mg BID dosing. Further the response was less than 20% of the response of rifampicin, an inducer of both CYP2B6 and 3A4. Overall, the CYP inhibition and induction data, along with the clinical observations to date [14,32], suggest that remogliflozin etabonate can be dosed with other drugs metabolized by CYP enzymes such as sulfonylureas, calcium channel blockers and statins without concern of a pharmacokinetic drug interaction.

The characterization of the interactions of remogliflozin etabonate with transporters and drug metabolizing enzymes, together with other clinical data, is a first step towards understanding the drug interaction potential between remogliflozin etabonate and other therapeutic agents. Many T2DM patients take multiple anti-diabetic drugs, as well as treatments for hypertension, heart failure and dyslipidemia. Such agents often include metformin, DPP-IV inhibitors, thiazolidinediones, sulfonylureas, digoxin and statins. The importance of understanding the potential interaction of transporters and enzymes is apparent with the possible co-administration of these drugs. For example, metformin, digoxin, rosuvastatin, and sitagliptin are not (extensively) metabolized but drug transporters have key roles in the disposition or efficacy of these compounds (see drugs labels at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm ). Metformin is a substrate for OCT1 and 2 [33,34], rosuvastatin is a substrate for OATP1B1 [35], digoxin is a Pgp substrate [36] and sitagliptin a substrate for OAT3 [37]. As remogliflozin etabonate and its metabolites are not strong inhibitors of transporters, there are expected to be no drug interactions between remogliflozin etabonate and these agents. Indeed, a clinical study with metformin and remogliflozin etabonate confirmed that there was no pharmacokinetic or dynamic interaction between these two anti-diabetic medicines [32]. Similarly, there are a number of expected co-administered drugs such as simvastatin, rosiglitazone and glimepiride that undergo extensive CYP-mediated metabolism [38-40]. As remogliflozin etabonate and its metabolites are not CYP inhibitors or inducers, it follows that interactions between these CYP substrates and remogliflozin etabonate are not expected.

In conclusion, remogliflozin etabonate and remogliflozin inhibit a number of SLC transporters (OATP1B1 and OCT) that are involved in the disposition of drugs used in the treatment of diabetes or its associated co-morbidities. The IC50 values are significantly higher than the expected peak plasma concentrations of remogliflozin following a 100 mg BID dosing schedule, supporting that the risk of drug interactions for other drugs when administered with remogliflozin etabonate and remogliflozin is low. Further, remogliflozin etabonate and its metabolites did not inhibit a number of other ABC and SLC transporters or CYP enzymes. These in vitro investigations along with pharmacokinetic studies in healthy volunteers and subjects with T2DM provide a mechanistic basis for elucidating clinical drug interactions by remogliflozin etabonate. This information has been used to guide the design of clinical studies with remogliflozin etabonate.

References
1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. (2000) Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412.

2. Tumer RC, Cull CA, Frigiti V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281: 2005-2012.

3. Nathan DM, Cleary PA, Backlund JY, Genth SM, Lachin JM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2653-2665.

4. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, et al. (2006) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963-1972.

5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596.

6. Papazafropoulou AK, Kardara MS, Pappas SI (2011) Challenges for the treatment of diabetes mellitus.. Recent Pat Endocr Metab Immune Drug Discov 5: 203-209.

7. Washburn WN (2009) Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 52: 1785-1794.

8. Idris I, Donnelly R (2009) Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11: 79-88.

9. Abdul-Ghani MA, Norton L, DeFronzo RA (2012) Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 12: 230-238.

10. Bakris GL, Fonseca VA, Sharma K, Wright EM (2009) Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 75: 1272-1277.

11. Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 20: 452-477.

12. Bays H (2009) From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 25: 671-681.

13. Jabbour SA, Goldstein BJ (2008) Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycemic control in patients with diabetes. Int J Clin Pract 62:1279-1284.

14. Dobbins RL, O’Connor-Semmes R, Kapur A, Kapliza C, Golor G, et al. (2012) Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 14: 15-22.

15. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H et al. (2008) Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327: 268-276.

16. Raulio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, et al. (2006) In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34: 786-792.

17. Polli JW, Humphreys JE, Harmon KA, Castellino S, O’Mara MJ, et al. (2008)
The role of efflux and uptake transporters in [N-(3-chloro-4-[[3-fluorobenzyl]oxy]phenyl)-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolin-amine (GW572016, lataplatin) disposition and drug interactions. Drug Metab Dispos 36: 695-701.

18. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, et al. (2002) Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300: 918-924.

19. Shardlow CE, Generaux GT, MacLauchtin CC, Pons N, Skordos KW, et al. (2011) Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Dispos 39: 2076-2084.

20. Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, et al. (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36: 1198-1201.

21. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT et al. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102: 1016-1023.

22. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, et al. (1999) Role of P-glycoprotein on the CNS disposition of ampanevir (141W94), an HIV protease inhibitor. Pharm Res 16: 1206-1212.

23. Solon EG, Balani SK, Luo G, Yang TJ, Haines PJ, et al. (2002) Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography. Drug Metab Dispos 30: 1164-1169.

24. Solon EG, Balani SK, Lee FW (2002) Whole-body autoradiography in drug discovery. Curr Drug Metab 3: 451-482.

25. Sigalaos JS, Bowers GD, Castellino S, Culp AG, Wagner DS, et al. (2012) The Absorption, Metabolism, and Excretion of Remogliflozin Etabonate, a Novel Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, in Humans: Evidence from In vitro Studies and Clinical Mass Balance and Ketoconazole Drug Interaction Studies. Drug Metab Dispos (Submitted).

26. Tsujihara K, Hongu M, Saito K, Kawanishi H, Kuriyama K, et al. (1999) Sodium-Dependent Glucose Co-Transporter-2 Inhibitor) and metformin when co-administered in type 2 diabetes mellitus patients. Diabetes 58: 582.

27. Tsujimoto M, Dan Y, Hirata S, Ohtani H, Sawada Y (2008) Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure. Drug Metab Pharmakokinet 23: 406-411.

28. Chu XY, Gleasby K, Yabut J, Cai X, Chan GH, et al. (2007) Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321: 673-683.

29. Deeks ED, Keam SJ (2007) Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs 67: 2747-2779.

30. Iwakawa S, Miyashita K, Hashimoto Y, Kuroda T (2006) Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3. Biol Pharm Bull 29: 1983-1985.

31. Neuvonen PJ, Backman JT, Niemi M (2008) Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47: 463-474.

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:
- 200 Open Access Journals
- 1,500 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing in PubMed (postal), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Options: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/jcmdgroup

Citation: Polli JW, Humphreys JE, Harmon KA, Webster LO, Reese MJ, et al. (2012) Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes. J Diabetes Metab 3:200. doi:10.4172/2155-6156.1000200

J Diabetes Metab
ISSN:2155-6156 JDM, an open access journal

Volume 3 • Issue 5 • 1000200